In viva extracellular unitary recordings, in vitro 3H-5-hydroxytryptamine (5-HT) uptake, and 3H-paroxetine binding assays were used to assess the effect of acute and long-term administration of the 5-HT reuptake inhibitor paroxetine on the neuronal 5-HT transporter in the rat dorsal hippocampus. Recovery time of the firing activity of CA, hippocampus pyramidal neurons following microiontophoretic application of 5-HT was used as an index of in vivo reuptake activity.
In a first series of experiments, the acute intravenous administration of paroxetine and 5-HT denervation with the neurotoxin 5,7-dihydroxytryptamine produced a marked prolongation of the suppressant effect of 5-HT, indicating that reuptake into 5-HT terminals plays a significant role in terminating the action of microiontophoretically applied 5-HT. In a second series of experiments, rats were treated with paroxetine (10 mg/kg/d, s.c.) for 2 or 21 d. In both treatment groups, there was a marked prolongation of the effect of microiontophoretically applied 5-HT; however, in rats treated for 2 d, the prolongation was significantly greater than that observed in rats treated for 21 d. After the 21 d treatment with paroxetine and a 48 hr washout, the prolongation of the effect of microiontophoretically applied 5-HT by acute intravenous paroxetine was significantly reduced, suggesting a decrease in the number of 5-HT carriers. In keeping with this interpretation, following the same treatment regimen, there was a 50% and 60% reduction of the in vitro3H-5-HT uptake in hippocampal and dorsal raphe slices, respectively, and a reduced effectiveness of paroxetine in blocking 3H-5-HT uptake in both regions. The Shydroxytryptamine (5-HT) reuptake process and 5-HT transporter have been widely studied in vitro using both )H-S-HT uptake and radioligand binding techniques (Marcusson and Ross, 1990) . In contrast, the characterization of 5-HT reuptake activity in vivo has not been so extensive, as studies have been mostly concerned with physiological, behavioral, or neurochemical consequences of reuptake inhibition (Fuller and Wong, 1990; Johnson, 199 1) . Using an in vivo electrophysiological paradigm, Wang et al. (1979) reported that 5-HT reuptake plays a significant role in terminating the action of microiontophoretically applied 5-HT onto lateral geniculate and amygdaloid neurons. However, the 5-HT reuptake process did not appear to play an important role in terminating the suppressant effect ofmicroiontophoretically applied 5-HT onto CA, pyramidal neurons (de Montigny et al., 1980) .
Reports on the occurrence of a downregulation of the 5-HT transporter following long-term antidepressant treatment are controversial. Radioligand binding studies indicate that the neuronal 5-HT transporter is associated with 3H-imipramine (Langer and Raisman, 1983 ) and 3H-paroxetine binding sites (Habert et al., 1985; Mellerup and Plenge, 1986) and that repeated administration of several classes of antidepressant drugs downregulate 3H-imipramine (Plenge and Mellerup, 1982; Brunello et al., 1987) , but not 3H-paroxetine, binding sites (Graham et al., 1987; Cheetham et al., 199 1; Foy et al., 199 1) . This controversy may stem in part from the observation that while 3H-paroxetine binds to a single population of sites selectively located on 5-HT neurites (Marcusson et al., 1988; Hrdina et al., 1990) , 3H-imipramine has been shown to label a heterogeneous population of sites in brain tissue (Reith et al., 1983; Marcusson et al., 1985) . Recently, Kovachich et al. (1992) , using 3H-cyanoimipramine to label the 5-HT transporter, have concluded that different types of antidepressants do not exert consistent effects on the density of 5-HT reuptake sites.
The present study was thus undertaken to address the following issues that remained unsolved: (1) to devise a reliable method for measuring electrophysiologically in vivo 5-HT reuptake activity; (2) to assess functionally the possibility of a desensitization of the 5-HT carrier following long-term reuptake blockade; and (3) to correlate functional modifications with changes in the 'H-paroxetine binding parameters following long-term reuptake blockade with paroxetine.
Materials and Methods
Treatments. Male Sprague-Dawley rats (175-200 gm) were implanted subcutaneously with an osmotic minipump (Alza, Palo Alto, CA) that delivered 10 or 20 mg/kg/d of paroxetine (SmithKline Beecham, Harlow, England) for 2 or 21 d. The drug was dissolved in a 50% ethanol: water solution, and control rats were implanted with a minipump containing the vehicle. Unless otherwise specified, the experiments were The Journal of Neuroscience, May 1994, 14(5) 3037 A. value is the time in seconds required by a neuron to recover by 50% its initial 0, firing frequency calculated from the termination ofthe microiontonhoretic an-1 1 2 2 Paroxetine (mg/kg, i.v.)
carried out with the osmotic minipump in place. Two weeks before the experiments, another series of rats received an intracerebroventricular injection of 5,7-dihydroxytryptamine (5,7-DHT; 200 rg of free base in 20 ~1 of 0.9% NaCl and 0.1% ascorbic acid). This treatment has been shown to reduce 5-HT content in CA, region by at least 90% (Gerson and Baldessarini, 1975) . Desipramine (25 mg/kg, i.p.) was administered 1 hr before 5,7-DHT to protect noradrenaline neurons (Bjorklund et al., 1975) . Control rats were injected with saline. All experiments were carried out under chloral hydrate anesthesia (400 mg/kg, i.p.). Electrophysiological experiments. Extracellular unitary recordings were obtained from pyramidal neurons in the CA, region of dorsal hippocampus. The microelectrode was descended 4 mm lateral and 4 mm anterior to lambda. Pyramidal neurons were identified by their highamplitude (0.5-I .2 mV), long-duration (0.6-l msec) complex spike discharges alternating with simple spike activity (Kandel and Spencer, 196 1) . A leak or a small current of ACh (O-5 nA) was used to activate the neurons within their physiological range (8-14 Hz; Ranck, 1975) . Microiontophoretic applications were performed with five-barreled glass micropipettes that were pulled in a conventional manner and their tips broken back to 10-I 5 pm under microscopic control. The central barrel, filled with 2 M NaCl solution, was used for extracellular unitary recording. Three of the side barrels contained three of the following solutions: 5-HT creatinine sulfate (5 mM in 200 mM NaCl, pH 4; Sigma, St. Louis, MO); norepinephrine (NE) (50 mM in 200 mM NaCl, pH 4; Sigma); gepirone (25 mM in 200 mM NaCl, pH 4; Bristol-Myers Squibb, Wallingford, CT); or ACh (20 mM in 200 mM NaCI, pH 4; Sigma). The fourth side barrel, containing a 2 M NaCl solution, was used for automatic current balancing. Ejection periods were always of 50 sec.
The responsiveness of CA, pyramidal neurons to microiontophoretic application of drugs was assessed using I. T,, and RT,, values calculated by on-line computer with a 0.1 set resolution. The I. r,, value represents the charge in nanocoulombs
(1 nC = 1 nA x 1 set) required to obtain a 50% decrease of the firing rate of the neuron recorded and has been shown to provide an index of the neuronal responsiveness to the microiontophoretically applied drug (de Montigny and Aghajanian, 1977; de Montigny et al., 1980) . The presynaptic component of neuronal responsiveness to microiontophoretic application of drugs was evaluated using the RT,, method. RT,, is defined as the time in seconds required by the neuron to recover 50% of its initial firing frequency from the termination of microiontophoretic application. The RT,, value has been shown to provide a reliable index of the in vivo activity of the NE reuptake process in the rat hippocampus (de Montigny et all, 1980; Gravel and de Montianv. 1987 ) and of the 5-HT carrier in the rat -_.
amygdala and lateral geniculate body (Wang et al., 1979) . Determination of in vitro 'H-5-HT uptake. For determination of in vitro 'H-5-HT uptake, animals were decapitated, their brains rapidly removed, and dissected on an ice-cold plate. Slices of 0.4 mm thickness from hippocampus or raphe region were prepared using a McIlwain chopper. They were incubated for 3 min at 37°C in a Krebs solution with various concentrations (O-1000 nM) of paroxetine, and bubbled with a mixture of 95% 0, and 5% CO,. The composition of the Krebs solution was 118 mM NaCl, 4.7 mM CaCl,, 1 mM NaH,PO,, 25 mM NaHCO,, 11.1 mM glucose, 0.004 mM Na,EDTA, and 0.11 mM ascorbic acid. After the incubation period, 'H-5-HT (specific activity, 22.7 Ci/ mmol; New England Nuclear Research Products, Mississauga, Ontario, Canada) was added at a final concentration of 5 nM, 20 nM, or 100 ntvr. Following a 3 min incubation period, uptake was terminated by transferring the slices to 5 ml ofice-cold buffer, and they were then solubilized in 0.5 ml of Soluene 350 (Packard Instruments, Downers Grove, IL). Radioactivity in the slices and the incubation medium was determined by liquid scintillation spectroscopy. Parallel experiments were carried out at 0°C as control for passive diffusion. All experiments were performed in duplicate and the amount of tritium actively captured by the tissue (C',) was calculated according to the formula C, = C, -C,, where C,. and C, are the tissuezdium ratios of 'H-5-HT at 37°C and 0°C respectively. Inhibition of uptake was calculated by means of the formula % of inhibition = [l -C,,/C,,] x 100, where C,, and C,, are the amounts ofactively captured 'H-5-HT in a medium with or without paroxetine, respectively. IC,, values for the uptake of 'H-5-HT were determined by computer analysis (GRAPHPAD, Graphpad Software, San Diego, CA) from concentration-effect curves based on four concentrations of paroxetine.
'H-paroxetine binding assays. Binding assays using -'H-paroxetine (25 Ci/mmol; New England Nuclear Research Products) were performed according to a previously described protocol (Marcusson et al., 1988) . Forty-eight hours after the removal of the osmotic minipump rats were decapitated, brains dissected, and cortex and hippocampus immediately frozen and kept at -70°C until the binding assays were carried out. Membranes were prepared by homogenizing brain tissue in 15 ml of ice-cold buffer (50 m&r Tris HCl, 120 mM NaCl, 5 mM KCI; pH 7.4) and centrifuging at 48,000 x g for 10 min at 4°C. The resulting pellet was suspended in 15 ml of buffer and centrifuged. The final pellet was suspended to a final tissue concentration of 40-60 pg protein/ml (approximately 0.75 mg wet weight/ml) in the binding assay. The homogenates were incubated with )H-paroxetine (0.03-2 nM) at 22°C in a final volume of 1600 PI for 60 min. Incubations were terminated by addition of 4 ml ice-cold buffer and filtration through Whatman GFX filters using a 24-channel cell harvester. Filters were then washed with four 4 ml rinses in cold buffer. Radioactivity trapped by the filters was determined by liquid scintillation spectroscopy (Beckman Counter LS 6000 SE, Beckman Instruments, Fullerton, CA). Nonspecific binding was estimated in the presence of 100 FM 5-HT. Binding was analyzed using the curve-fitting program LIGAND (G. A. McPherson, Elsevier-Biosoft, Cambridge, UK).
Statistical analysis. Results were expressed throughout as means + SEM. When two means were compared, statistical significance of their difference was assessed using the two-tailed paired or nonpaired Student's t tests as indicated. For multiple comparisons, one-way or twoway ANOVA was used for independent and paired samples, respectively.
Results
Eflect of acute intravenous administration of paroxetine on the recovery time from microiontophoretic applications of 5HT
The duration of suppression following 5-HT applications was assessed in naive rats using increasing currents for applying A. were increased by 206%, 145%, and 1 1 O%, respectively.
In order to confirm the selectivity of paroxetine for the 5-HT carrier in this paradigm, the effect of paroxetine was assessed on the recovery from microiontophoretic applications of the 5-HT,, agonist gepirone and NE, neither ofwhich are substrates for the 5-HT transporter. In contrast to the prolongation of the effect observed for 5-HT, the RT,, values for these two compounds were not affected by successive doses of paroxetine (Fig.   3 , Table 1 Effect of 5-HT denervation on the recovery from microiontophoretic applications of 5-HT The prolongation of the recovery time from microiontophoretic applications of 5-HT, following acute 5-HT reuptake blockade, in the absence of a modification of its initial effectiveness [I. T,, values: 23 ? 3 nC prior to, and 25 * 4 nC following, paroxetine (4 mg/kg, iv.; n = 14)], suggested a pure presynaptic effect of paroxetine. This interpretation relied, however, on the assumption that the recovery of the firing rate of CA, pyramidal neurons from microiontophoretic applications of 5-HT is exerted mainly by the 5-HT transporters located on 5-HT terminals. To verify this hypothesis, the recovery from 5-HT applications was assessed in 5,7-DHT-lesioned rats. As expected, 5-HT denervation markedly prolonged the effect of 5-HT: the RT,, values were increased by 324%, 262%, and 197% for 5 nA, 10 nA, and 20 nA applications, respectively (Fig. 4A) . In- Figure 4 . A, Recovery time, expressed as RT,, values (means + SEM), of dorsal hippocampus CA, pyramidal neurons from microiontophoretic applications of 5-HT in control rats and in rats treated with 5,7-DHT, before and after intravenous administration of 4 mg/kg of paroxetine. *, p < 0.00 1 compared to control values using two-tailed Student's t test. B, Effect of intravenous paroxetine on pyramidal neuron firing frequency in control and 5,7-DHT-lesioned rats. t, p < 0.0 1 using two-tailed paired Student's t test. The number of neurons tested is given at the bottom of each column.
terestingly, as shown in Figure 4A , the injection of paroxetine (4 mgkg, i.v.) in 5,7-DHT-lesioned rats did not produce a further increase in RT,,, indicating that pretreatment with 5,7-DHT had produced a complete denervation and that the effect of paroxetine observed in intact rats (Figs. 1, 2) was entirely attributable to the blockade of the 5-HT transporters located on 5-HT terminals.
In intact rats, intravenous administration of paroxetine per se reduced pyramidal neuron firing frequency. Consequently, the microiontophoretic current of the ACh had to be increased from 4 + 0.7 to 9 ? 0.8 nA (n = 6) to restore the firing rate to its preinjection level. Brunel and de Montigny (1987) have previously demonstrated that ACh does not alter the response of pyramidal neurons to 5-HT. In 5,7-DHT-lesioned rats, paroxetine had no effect on the firing frequency of pyramidal neurons (n = 6; Fig. 4B ).
It is also noteworthy that 5,7-DHT lesion and administration of paroxetine (10 mg/kg/d, s.c.) for 2 d yielded nearly identical RT,, values. When the RT,, values from 5-HT applications were . . assessed in rats that were still carrying the osmotic minipump during the experiment, this parameter was increased by 320%, 270%, and 2 12% for 5, 10, and 20 nA currents, respectively (as compared to 324%, 262%, and 197% for the same currents in 5,7-DHT-lesioned rats). This suggests that, at a dose of paroxetine of 10 mg/kg/d, all the 5-HT transporters were blocked, Table 2 ) thereby confirming that the 10 mg/kg/d dose of paroxetine maximally inhibits 5-HT reuptake.
Effect of long-term administration of paroxetine on the recovery time from microiontophoretic applications of 5-HT To test the effect of long-term reuptake blockade on the 5-HT transporter, the effectiveness of successive intravenous doses (l-2 mg/kg) of paroxetine to prolong RT,, values was assessed in control and paroxetine-treated rats (10 mg/kg/d, S.C. x 2 1 d) following a 48 hr washout period to ensure complete drug elimination. As exemplified in Figure 5 , the effectiveness of acute intravenous paroxetine was reduced in the paroxetine-treated group. Before the injection of paroxetine, the RT,, values were similar in treated and in control rats (Fig. 6) , indicating, first, that the reuptake process was no longer blocked after the washout period, and second, that at the concentrations attained with the different microiontophoretic currents of 5-HT used, the ability of 5-HT terminals to take up 5-HT was unchanged after long-term blockade by paroxetine. The first dose of paroxetine (1 mg/kg, i.v.) increased the RT,, values to a similar extent in control and long-term paroxetine-treated rats. However, subsequent cumulative doses of 2 and 4 mg/kg produced smaller effects in long-term paroxetine-treated rats than in controls (Figs. 5, 7), indicating a decreased efficacy of intravenous paroxetine in blocking 5-HT reuptake following long-term paroxetine treatment. For all currents used, the dose of paroxetine required to increase RT,, values by 50% (ED,,) was doubled in long-term paroxetine-treated rats (Table 3) .
To investigate further the induction of a "tolerance" by longterm paroxetine administration, the suppressant effect of 5-HT was determined in control rats and in rats treated with paroxetine (10 mg/kg/d, s.c.) for 2 or 2 1 d without removing the osmotic pump. For all currents used, recovery from microiontophoretic applications of 5-HT was prolonged in both treated groups, but to a significantly lesser extent in long-term-than in short-term-treated rats (Fig. 8) . The RT,, values from 5, 10, and 20 nA applications of 5-HT were increased by 377%, 300%, and 198% in 2 d paroxetine-treated rats, and by 254%, 196%, and 149% in 21 d paroxetine-treated rats (Fig. 9) .
Recovery from microiontophoretic applications of gepirone was unchanged by long-term administration of paroxetine, in keeping with the fact that it is not a substrate for the 5-HT transporter. RT,, values from 4 and 10 nA applications of gepirone were 28 + 4 set and 53 f 8 set in control rats, and 24 f 4 set and 50 ? 6 set in rats treated with paroxetine for 21 d. The initial responsiveness (I. T,,, values) to microiontophoretic applications of gepirone and of 5-HT was also unchanged following long-term paroxetine treatment, ruling out the possibility that the reduced effectiveness of acute paroxetine to prolong the effect of 5-HT could be ascribed to a decrease in neuronal responsiveness to the activation of postsynaptic 5-HT,, receptors. Eflect of long-term paroxetine administration on in vitro -'H-5-HT uptake The following series of experiments were carried out to verify in vitro the induction of desensitization of the 5-HT transporter by long-term paroxetine administration. In control experiments, increasing the concentration of paroxetine in the incubation medium caused a concentration-dependent reduction in the amount of radioactivity captured by the slices. In slices from 5,7-DHT-lesioned rats, the uptake of 3H-5-HT was reduced by 70% (Fig. 10) . Moreover, the incubation with increasing paroxetine concentrations did not produce further inhibition (Fig. 10) . As 3H-5-HT uptake in control slices incubated with the highest paroxetine concentration (1000 nM) was not significantly different from that observed after 5,7-DHT lesion, it can be assumed that maximal blockade of 5-HT uptake sites was attained at this concentration. In slices from control rats, paroxetine in the incubation medium was more effective in blocking reuptake using a 100 nM than a 5 nM concentration of3H-5-HT (Fig. 1 lD,F) . From each of these paroxetine concentration-effect curves, the concentration of paroxetine inducing 50% of the maximal inhibition (attained with 1000 nM paroxetine) was determined. Paroxetine was six times more potent in blocking reuptake when the 3H-5-HT concentration in the incubation medium was high (100 nM) than when it was low (5 nM): respective calculated IC,, values were 18 nM and 107 nM. Following a 48 hr washout period, in slices incubated with 100 nM XH-5-HT, radioactivity taken up by the tissue was reduced by 50% in the long-term paroxetine-treated group. This effect was significant in slices incubated with 100 nM 3H-5-HT and with paroxetine concentrations lower than 1000 nM (Fig.   11A ).
Following long-term treatment with paroxetine, the in vitro effectiveness of paroxetine to block 5-HT uptake was reduced by 43%, thus confirming results from electrophysiological experiments reported above. However, this in vitro effect was only seen when incubation was carried out in the presence of 5 nM 3H-5-HT (Fig. 11F) . When slices were incubated with 20 nM 3H-5-HT, long-term paroxetine treatment did not have any detectable effect (Fig. 1 l&E) . Moreover, it is noteworthy that after long-term paroxetine treatment the difference in IC,, for paroxetine at different 3H-5-HT concentrations was abolished. Calculated IC,, values were 14 nM and 13 nM for 3H-5-HT concentrations of 5 nM and 100 nq respectively. The effect of long-term reuptake blockade was also assessed in slices from the raphe region. It induced changes similar to those observed in the hippocampus: 3H-5-HT uptake was reduced by 60% (Fig. 12A ) and 10 nM, but not 100 nM, of paroxetine produced a much smaller inhibition of 3H-5-HT uptake than in slices from control rats (Fig. 12B) .
Effect of long-term paroxetine administration on jHparoxetine binding parameters Specific saturable binding of 3H-paroxetine to rat cortical and hippocampal membranes was concentration dependent (28% specific binding at 2 nM 'H-paroxetine).
Scatchard transformation of the binding data produced linear plots in all cases (Fig. 13 ) and fitted better a one-rather than a two-site model. Mean Kd and B,,, values in control and long-term paroxetinetreated rats for both regions are summarized in Table 4 . After long-term paroxetine administration, the total number of binding sites was reduced by 60% in cortex and by 70% in hippocampus, thus confirming a downregulation of the 5-HT transporter. The fact that Kd values remained unchanged after the treatment ruled out the possibility that the changes observed could be due to a competitive inhibition of binding by residual paroxetine after the 48 hr washout period.
Discussion
Electrophysiological data obtained in the present study confirm and extend previous observations that RT,, values following 'H-5-HT reuptake activity (4-C) and effectiveness of paroxetine to inhibit 3H-5-HT reuptake, expressed as percentage of uptake inhibition (D-q in hippocampal slices from control (n = 5; 0) and long-term paroxetine-treated rats (n = 5; 0) (10 mg/kg/d, S.C. x 21 d + 48 hr washout). *, p < 0.02 as compared to control values using nonpaired Student's t test; t, p < 0.05 as compared to control using nonpaired Student's t test. microiontophoretic applications of 5-HT provide a reliable index of the in viva activity of the 5-HT reuptake process, since it is prolonged three-to fourfold by acute, short-term, and longterm administration of paroxetine (Figs. 2, 9 ) as well as by lesioning 5-HT terminals (Fig. 4) . The fact that a selective 5-HT reuptake inhibitor @SRI) prolongs recovery from 5-HT applications, leaving unaffected the effects of gepirone and NE (Table  I) , which are not substrates for the 5-HT transporter, strongly suggests that the recovery of the firing frequency of pyramidal neurons following microiontophoretic applications of 5-HT depends on the activity of the 5-HT carrier. In a previous report we had concluded that, in dorsal hippocampus, 5-HT reuptake did not play a significant role in terminating the action of microiontophoretically applied 5-HT (de Montigny et al., 1980) . The apparent contradiction between the latter report and the present one is probably due to the fact that, herein, microiontophoretic applications were carried out using higher currents of a more concentrated solution of 5-HT to ensure that it would diffuse from the ejection site (near the cell body) to strata radiatum and oriens, where the majority of 5-HT terminals are located (Oleskevich and Descarries, 1990) .
In keeping with previous observations that lesioning of 5-HT terminals abolishes 3H-paroxetine binding (de Souza and Kuyatt, 1987; Hrdina et al., 1990; Dewar et al., 199 l) , in our electrophysiological paradigm the 5,7-DHT pretreatment completely abolished the effect of acute paroxetine on the duration of suppression of firing activity by the microiontophoretic application of 5-HT (Fig. 4A) . A similar effect was observed in vitro where paroxetine failed to decrease 3H-5-HT uptake in slices obtained from 5,7-DHT-lesioned rats (Fig. 10) . Even if 5-HT transporters have been found in primary astrocyte cultures from neonatal rat brain the majority of by 5-HT terminals . Our results further support the notion that functionally relevant transporters are confined to 5-HT terminals.
The electrophysiological paradigm we devised was not only sensitive enough to detect the effect of paroxetine on exogenously applied 5-HT through changes in RT,,, but it could also detect the effect of 5-HT reuptake blockade on endogenously released 5-HT via the reduction of pyramidal neuron firing frequency (Figs. lB, 4B, 5A ). Since denervation abolished the consistent suppressant effect produced by paroxetine (Fig. 4B) on pyramidal neuron firing frequency, the latter observation clearly demonstrates the physiological role played by the 5-HT transporter in terminating the action of endogenously released 5-HT.
Long-term paroxetine treatment results in adaptive changes of the 5-HT transporter. These changes were detected not only in hippocampus (Figs. 7, 9, 11) but also in cerebral cortex (Fig.  13 ) and in the raphe region (Fig. 12) indicating that 5-HT transporters in multiple pre-and postsynaptic regions of the rat CNS share the ability to adapt to their sustained occupation.
Though previous studies using 3H-imipramine have reported a decreased number of binding sites following long-term antidepressant treatment (Barbaccia et al., 1983; Arora and Meltzer, 1986; Brunello et al., 1987 ) these studies did not take into account the heterogeneity of 3H-imipramine binding sites. In the present study, the use of paroxetine as the tritiated ligand allows us to conclude that the changes observed are directly related to the 5-HT transporter as it has been shown to selectively label this carrier. In contrast with our observations, Graham et al. (1987) , Brunswick et al. (199 l), and Cheetham et al. (1991) using 3H-paroxetine, and Hrdina et al. (1990) taking into account high-and low-affinity 'H-imipramine binding sites, did not detect any change in B,,, following long-term antidepressant treatment. These divergent results could be explained by the fact that in the aforementioned studies reuptake blockers were administered by intraperitoneal injections. Since SSRIs have been shown to be rapidly metabolized in rodents (Buus Lassen, 1978; Fredricson, 1982) intraperitoneal injections, given usually every 12 or 24 hr, lead to large fluctuations in drug plasma levels, and consequently in the degree of reuptake blockade. For example, for the SSRI citalopram, which in rats has a half-life of 3 hr (Fredricson, 1982) its suppressant effect on the firing activity of 5-HT neurons is no longer detectable 15 hr after the injection of a high dose (Chaput et al., 1986) . The observation of the lack of 5-HT reuptake blockade 48 hr after a 2 1 d treatment (Fig. 6) is thus fully consistent with the rapid metabolism of paroxetine in rodents (Buus Lassen, 1978) . In the present study, to avoid fluctuations and produce stable plasma levels throughout the treatment period, paroxetine was administered by sustained subcutaneous infusion. Interestingly, Lesch et al. (1993) have recently reported the induction ofdownregulation of 5-HT transporter mRNA following long-term subcutaneous administration of fluoxetine, imipramine, and chlorimipramine. It therefore seems that stable plasma concentrations of the reuptake blocker administered are essential for the induction of an adaptive response at the level of the 5-HT transporter. Moreover, Kovachich et al. (1992) have reported that intraperitoneal administration of sertraline, but not that of citalopram, can reduce 3H-cyanoimipramine binding in different limbic regions. The fact that desmethylsertraline is more potent and has a longer half-life than mono-and dimethylated citalopram metabolites (Boyer and Feighner, 199 1) further supports the notion that a sustained occupation is required to induce a downregulation of the neuronal 5-HT transporter. Since Lesch et al. (1993) using 5-HT reuptake inhibitors less potent than paroxetine, still observed a downregulation of the mRNA encoding the 5-HT transporter, it is improbable that uptake blocking capacity of the different SSRI might account for the differences between this and previous studies (Graham et al., 1987; Hrdina et al., 1990; Brunswick et al., 199 1; Cheetham et al., 1991) .
In the present electrophysiological experiments, desensitization of the 5-HT transporter in long-term paroxetine-treated rats was evidenced by a reduction in the effectiveness of acute paroxetine to prolong the duration of suppression of firing by microiontophoretic applications of 5-HT (Fig. 7) . Indeed, the ED,, of intravenous paroxetine to prolong RT,, was doubled in long-term paroxetine-treated rats (Table 3) . Furthermore, the effect of subcutaneous administration of paroxetine on RT,, was significantly smaller in rats treated for 2 1 d than in those treated for 2 d (Fig. 9) . Since the prolongation of RT,, values produced by 2 d subcutaneous administration of 1 O/mg/kg/d of paroxetine was similar in magnitude to that produced by a dose of 20 mgl kg/d, it can be assumed that, at the dose of lO/mg/kg/d, paroxetine blocked all available uptake sites. The fact that the effect of the 2 d treatment with 1 O/mg/kg/d of paroxetine was greater than that of the 21 d treatment suggests that the mechanism underlying this tolerance could be a reduction in the number of S-HT transporters. This assumption was confirmed by radioligand binding studies that showed a 70% decrease in the number of 3H-paroxetine binding sites in hippocampal membranes following long-term paroxetine administration (Fig. 13A) .
The current model for the 5-HT transporter proposes that 5-HT, tricyclic, and nontricyclic uptake inhibitors all bind to the same or overlapping sites on the carrier (Marcusson et al., 1989; Marcusson and Ross, 1990) . There is an apparent discrepancy between the reduced effectiveness of acute injection of paroxetine (Fig. 7) , the reduced 3H-5-HT uptake (Fig. 1 l) , and the reduced number of )H-paroxetine binding sites (Fig.  12) 48 hr after the long-term paroxetine treatment, indicating a decrease in the number of 5-HT transporters, and the observation that, at this time point, the effect of microiontophoretically applied 5-HT was not prolonged (Fig. 6 ). This could be explained by the presence of spare 5-HT transporters. Hence, even if the long-term paroxetine treatment downregulates 5-HT transporter sites, the number of remaining sites would be sufficient to take up all of the microiontophoretically applied 5-HT, even when applied with the highest current (20 nA) used. This explanation is all the more likely since 5-HT is applied at the level of the soma, so that only minute amounts of the neurotransmitter would actually reach the 5-HT terminals, located mostly on remote dendritic trees. The existence of spare transporters could also explain the observation that, although paroxetine is a competitive antagonist for 5-HT reuptake, its IC,, was six times higher at 5 nM than at 100 nM 3H-5-HT concentrations. At the low 3H-5-HT concentration (5 nM), before interfering with 3H-5-HT uptake, paroxetine would first need to occupy a large number of sites, thus explaining the high IC,, values observed in these conditions. At the high 3H-5-HT concentration (100 nM), all (or most) of the transporters being operant, even low doses of paroxetine can interfere with reuptake. A reduction in the number of 5-HT transporters could also explain the fact that IC,, values for paroxetine at different )H-5-HT concentrations did not differ any longer following longterm paroxetine treatment since the number of spare sites would be minimal.
The proportion of occupied/free transporters could then explain the different ways in which desensitization was expressed in the in vitro reuptake experiments (Fig. 11 ). At 100 nM 'H-5-HT (when all transporters are operant) a reduction in the number of sites was detected by reduction in 3H-5-HT uptake capacity, whereas at the low concentration of 3H-5-HT (5 nM), even in the presence of a reduced number of transporters, the remaining ones were in sufficient number to take up as much radioactivity as the control slices. Thus, in the latter condition, the reduction in the number of transporters was reflected by a decreased efficacy of the maximally effective paroxetine concentration (1000 nM).
The reduction in 3H-paroxetine binding sites after long-term paroxetine administration confirms the downregulation of 5-HT transporters. The fact that Kd values were unchanged after treatment rules out the possibility of affinity changes being involved in the desensitization mechanism. This is in agreement with the observation that, even though paroxetine and 5-HT show different affinity for the 5-HT transporter, the present functional electrophysiological and uptake studies show that 5-HT reuptake activity and paroxetine effectiveness were reduced to a similar extent (45-60%) after long-term reuptake blockade,
